Page last updated: 2024-10-27

fluconazole and HIV

fluconazole has been researched along with HIV in 20 studies

Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.
fluconazole : A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.

HIV: Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2.

Research Excerpts

ExcerptRelevanceReference
"The AmBisome Therapy Induction Optimization (AMBITION-cm) trial, conducted in eastern and southern Africa, showed that a single, high dose (10 mg/kg) of liposomal amphotericin B, given with an oral backbone of fluconazole and flucytosine, was noninferior to the World Health Organization (WHO)-recommended regimen of 7 days of amphotericin B deoxycholate plus flucytosine for treatment of human immunodeficiency virus (HIV)-associated cryptococcal meningitis and has been incorporated into WHO treatment guidelines."5.69How Applicable Is the Single-Dose AMBITION Regimen for Human Immunodeficiency Virus-Associated Cryptococcal Meningitis to High-Income Settings? ( Boulware, DR; Harrison, TS; Hosseinipour, MC; Jarvis, JN; Lawrence, DS; Lortholary, O; Meintjes, G; Mosepele, M; Mwandumba, HC, 2023)
"Cryptococcal antigen screening is recommended among people living with AIDS when entering HIV care with a CD4 count of <100 cells/μl, and preemptive fluconazole monotherapy treatment is recommended for those with subclinical cryptococcal antigenemia."5.20Increased Antifungal Drug Resistance in Clinical Isolates of Cryptococcus neoformans in Uganda. ( Achan, B; Akampurira, A; Alhadab, AA; Boulware, DR; Hullsiek, KH; McDonald, TR; Meya, DB; Nielsen, K; Okagaki, LH; Rhein, JR; Smith, KD, 2015)
"HIV-uninfected CM patients who received high-dose fluconazole (800 mg/d) for initial therapy in Huashan Hospital were included in this retrospective study from January 2013 to December 2018."4.31Induction therapy with high-dose fluconazole plus flucytosine for human immunodeficiency virus-uninfected cryptococcal meningitis patients: Feasible or not? ( Cheng, JH; Jiang, YK; Luo, Y; Wang, X; Zhao, HZ; Zhou, LH; Zhu, LP; Zhu, RS, 2023)
"The objective of this study was to determine the pharmacokinetics of fluconazole after oral administration in children with human immunodeficiency virus (HIV) infection."3.69Pharmacokinetics of fluconazole after oral administration in children with human immunodeficiency virus infection. ( Brady, MT; Nahata, MC, 1995)
"When mycoses are diagnosed early and treated with the appropriate drugs, favorable therapeutic outcomes can be achieved."1.72Fungal esophagitis associated with tuberculous pericarditis in an human immunodeficiency virus-positive patient: a case report. ( de Lima-Neto, RG; de Melo, HRL; de Sousa, BR; Neves, RP; Silva, GM; Torres, KB, 2022)
"Fluconazole 1200mg was prescribed to 29 (63%) patients."1.46[Fluconazole 1200mg or 800mg for cryptococcal meningitis treatment in Ivory Coast]. ( Doumbia, A; Eholié, SP; Ehui, E; Ello, NF; Kassi, FK; Kassi, NA; Keita, M; Kouakou, GA; Mossou, C; Tanon, A, 2017)
"Cryptococcosis is rare among children, only occurring in about 1% of children with HIV."1.38Disseminated cryptococcosis in an HIV-positive boy. ( Friedman, D; Kongthavonsakul, K; Oberdorfer, P, 2012)

Research

Studies (20)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's3 (15.00)18.2507
2000's4 (20.00)29.6817
2010's6 (30.00)24.3611
2020's7 (35.00)2.80

Authors

AuthorsStudies
Zhao, HZ1
Cheng, JH1
Zhou, LH1
Luo, Y1
Zhu, RS1
Jiang, YK1
Wang, X1
Zhu, LP1
Harrison, TS1
Lawrence, DS1
Mwandumba, HC1
Boulware, DR2
Hosseinipour, MC1
Lortholary, O1
Meintjes, G1
Mosepele, M1
Jarvis, JN1
Silva, GM1
de Sousa, BR1
Torres, KB1
Neves, RP1
de Melo, HRL1
de Lima-Neto, RG1
Samukawa, S3
Yoshimi, R3
Kojitani, N3
Uzawa, Y3
Takase-Minegishi, K3
Kirino, Y3
Soejima, Y3
Kato, H3
Nakajima, H3
Monzani, V1
Córdoba, S1
Vivot, M1
Arias, B1
Vivot, W1
Szusz, W1
Castellaro, P1
Appendino, A1
Taverna, CG1
Otto, SBJ1
George, PE1
Mercedes, R1
Nabukeera-Barungi, N1
Warrell, CE1
Macrae, C1
McLean, ARD1
Wilkins, E1
Ashley, EA1
Smithuis, F1
Tun, NN1
Brilhante, RSN1
Guedes, GMM1
Silva, MLQD1
Castelo-Branco, DSCM1
Cordeiro, RA1
Sidrim, JJC1
Rocha, MFG1
Yang, JJ1
Huang, CH1
Liu, CE1
Tang, HJ1
Yang, CJ1
Lee, YC1
Lee, KY1
Tsai, MS1
Lin, SW1
Chen, YH1
Lu, PL1
Hung, CC1
Smith, KD1
Achan, B1
Hullsiek, KH1
McDonald, TR1
Okagaki, LH1
Alhadab, AA1
Akampurira, A1
Rhein, JR1
Meya, DB1
Nielsen, K1
Das, PP1
Saikia, L1
Nath, R1
Phukan, SK1
Kouakou, GA1
Ello, NF1
Kassi, NA1
Keita, M1
Doumbia, A1
Mossou, C1
Kassi, FK1
Tanon, A1
Ehui, E1
Eholié, SP1
Friedman, D1
Kongthavonsakul, K1
Oberdorfer, P1
Lilly, EA1
Shetty, KV1
Leigh, JE1
Cheeks, C1
Fidel, PL1
Legout, L1
Assal, M1
Rohner, P1
Lew, D1
Bernard, L1
Hoffmeyer, P1
Nahata, MC1
Brady, MT1
Gripshover, BM1
Valdez, H1
Salata, RA1
Lederman, MM1
Powderly, WG1
Ford, BJ1
Barr, D1
Smart, T1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Adjunctive Sertraline for the Treatment of HIV-Associated Cryptococcal Meningitis[NCT01802385]Phase 3460 participants (Actual)Interventional2015-03-09Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Center for Epidemiologic Studies in Depression (CES-D) Scale

Center for Epidemiologic Studies in Depression (CES-D) scale at 14 weeks. CES-D scores are based on a 20 item survey with total scores ranging from 0 to 60. Higher scores suggest a greater presence of depressive symptoms. A CES-D score of 16 or higher is interpreted to indicate a risk for depression. (NCT01802385)
Timeframe: 14 weeks

Interventionscore on a scale (Mean)
Placebo16.6
Sertraline 400mg13.2

Count of Participants With Cerebrospinal Fluid Sterility

Number of participants with sterile cerebrospinal fluid at 2 weeks (NCT01802385)
Timeframe: 14 days

InterventionParticipants (Count of Participants)
Placebo90
Sertraline 400mg101

Event Free Survival

Event free survival of composite events of: death,central nervous system (CNS) cryptococcal-related paradoxical immune reconstitution inflammatory syndrome (IRIS) or culture-positive relapse. (NCT01802385)
Timeframe: 18 weeks

InterventionParticipants (Count of Participants)
Placebo116
Sertraline 400mg103

Number of Participants Experiencing IRIS OR Relapse

Cumulative incidence of central nervous system (CNS) cryptococcal-related paradoxical immune reconstitution inflammatory syndrome (IRIS) or culture-positive relapse (NCT01802385)
Timeframe: 18 weeks

InterventionParticipants (Count of Participants)
Placebo9
Sertraline 400mg5

Quantitative Neurocognitive Performance Score (QNPZ-8)

Quantitative neurocognitive performance Z-score (QNPZ-8) at 14 weeks. The QNPZ-8 is a mean score of testing of 8 neurocognitive domains. Eqach domain is scaled based on a Z-score where the mean = 0 for the HIV-negative Ugandan population, accounting for age and educational status. Each +1 unit is one standard deviation better than the population norm. Each -1 unit is one standard deviation worse than the population norm. (NCT01802385)
Timeframe: 14 weeks

Interventionscore (Mean)
Placebo-1.4
Sertraline 400mg-1.3

Safety (Occurence of Adverse Events)

Safety and tolerability of adjunctive sertraline (grade 4-5) adverse reactions (NCT01802385)
Timeframe: 18 weeks

Interventionevents (Number)
Placebo121
Sertraline 400mg141

Survival

18-week survival. The comparison will be between sertraline 400mg group and placebo (NCT01802385)
Timeframe: 18 weeks

InterventionParticipants (Count of Participants)
Placebo125
Sertraline 400mg109

Fungal Clearance as Determined by Early Fungicidal Activity of CDF

To determine whether adjunctive sertraline will lead to a faster rate of fungal clearance from cerebrospinal fluid (CSF), as measured by early fungicidal activity (EFA) of clearance of the Cryptococcus colony forming units (cfu) per mL of CSF per day, compared to standard therapy alone. (NCT01802385)
Timeframe: 14 days

,
Intervention-log10 CFU/ml/day (Mean)
General Linear RegressionMixed-Effects Regression
Placebo0.470.33
Sertraline 400mg.43.33

Reviews

1 review available for fluconazole and HIV

ArticleYear
Current approach to the acute management of cryptococcal infections.
    The Journal of infection, 2000, Volume: 41, Issue:1

    Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; CD4 Lymphocyte Count; Cryp

2000

Trials

2 trials available for fluconazole and HIV

ArticleYear
How Applicable Is the Single-Dose AMBITION Regimen for Human Immunodeficiency Virus-Associated Cryptococcal Meningitis to High-Income Settings?
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2023, 03-04, Volume: 76, Issue:5

    Topics: Antifungal Agents; Drug Therapy, Combination; Fluconazole; Flucytosine; HIV; HIV Infections; Humans;

2023
Increased Antifungal Drug Resistance in Clinical Isolates of Cryptococcus neoformans in Uganda.
    Antimicrobial agents and chemotherapy, 2015, Volume: 59, Issue:12

    Topics: Amphotericin B; Antifungal Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Coinfection; Cr

2015

Other Studies

17 other studies available for fluconazole and HIV

ArticleYear
Induction therapy with high-dose fluconazole plus flucytosine for human immunodeficiency virus-uninfected cryptococcal meningitis patients: Feasible or not?
    Mycoses, 2023, Volume: 66, Issue:1

    Topics: Antifungal Agents; Drug Therapy, Combination; Fluconazole; Flucytosine; HIV; HIV Infections; Humans;

2023
Fungal esophagitis associated with tuberculous pericarditis in an human immunodeficiency virus-positive patient: a case report.
    Journal of medical case reports, 2022, Nov-07, Volume: 16, Issue:1

    Topics: Adult; Antifungal Agents; Candidiasis; Esophagitis; Fluconazole; HIV; Humans; Male; Mycoses; Pericar

2022
Cryptococcal meningitis with atypical paradoxical inflammatory reactions after antifungal treatment in acquired immune deficiency syndrome: A case report.
    Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2023, Volume: 29, Issue:3

    Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Ag

2023
Cryptococcal meningitis with atypical paradoxical inflammatory reactions after antifungal treatment in acquired immune deficiency syndrome: A case report.
    Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2023, Volume: 29, Issue:3

    Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Ag

2023
Cryptococcal meningitis with atypical paradoxical inflammatory reactions after antifungal treatment in acquired immune deficiency syndrome: A case report.
    Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2023, Volume: 29, Issue:3

    Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Ag

2023
Cryptococcal meningitis with atypical paradoxical inflammatory reactions after antifungal treatment in acquired immune deficiency syndrome: A case report.
    Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2023, Volume: 29, Issue:3

    Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Ag

2023
Cryptococcal meningitis with atypical paradoxical inflammatory reactions after antifungal treatment in acquired immune deficiency syndrome: A case report.
    Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2023, Volume: 29, Issue:3

    Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Ag

2023
Cryptococcal meningitis with atypical paradoxical inflammatory reactions after antifungal treatment in acquired immune deficiency syndrome: A case report.
    Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2023, Volume: 29, Issue:3

    Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Ag

2023
Cryptococcal meningitis with atypical paradoxical inflammatory reactions after antifungal treatment in acquired immune deficiency syndrome: A case report.
    Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2023, Volume: 29, Issue:3

    Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Ag

2023
Cryptococcal meningitis with atypical paradoxical inflammatory reactions after antifungal treatment in acquired immune deficiency syndrome: A case report.
    Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2023, Volume: 29, Issue:3

    Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Ag

2023
Cryptococcal meningitis with atypical paradoxical inflammatory reactions after antifungal treatment in acquired immune deficiency syndrome: A case report.
    Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2023, Volume: 29, Issue:3

    Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Ag

2023
A case report of catheter-related bloodstream infection due to Trichosporon coremiiforme in a patient with secondary neutropenia to HIV.
    Journal de mycologie medicale, 2020, Volume: 30, Issue:1

    Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Antitubercular Agents; Bacteremia; Catheter-R

2020
Cryptococcal meningitis and immune reconstitution inflammatory syndrome in a pediatric patient with HIV after switching to second line antiretroviral therapy: a case report.
    BMC infectious diseases, 2020, Jan-21, Volume: 20, Issue:1

    Topics: AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Antifungal Agents; Antigens, Fungal

2020
Ambulatory induction phase treatment of cryptococcal meningitis in HIV integrated primary care clinics, Yangon, Myanmar.
    BMC infectious diseases, 2021, Apr-21, Volume: 21, Issue:1

    Topics: Administration, Intravenous; Administration, Oral; Adolescent; Adult; AIDS-Related Opportunistic Inf

2021
A proposal for antifungal epidemiological cut-off values against Histoplasma capsulatum var. capsulatum based on the susceptibility of isolates from HIV-infected patients with disseminated histoplasmosis in Northeast Brazil.
    International journal of antimicrobial agents, 2018, Volume: 52, Issue:2

    Topics: Amphotericin B; Antifungal Agents; Brazil; Caspofungin; Echinocandins; Fluconazole; Histoplasma; His

2018
Multicenter study of trimethoprim/sulfamethoxazole-related hepatotoxicity: incidence and associated factors among HIV-infected patients treated for Pneumocystis jirovecii pneumonia.
    PloS one, 2014, Volume: 9, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Anti-Infective Agents; Arylamine N-Acetyltransferas

2014
Species distribution & antifungal susceptibility pattern of oropharyngeal Candida isolates from human immunodeficiency virus infected individuals.
    The Indian journal of medical research, 2016, Volume: 143, Issue:4

    Topics: Adolescent; Adult; Aged; Antiretroviral Therapy, Highly Active; Candida; Candidiasis; Child; Child,

2016
[Fluconazole 1200mg or 800mg for cryptococcal meningitis treatment in Ivory Coast].
    Journal de mycologie medicale, 2017, Volume: 27, Issue:1

    Topics: Adult; AIDS-Related Opportunistic Infections; Antifungal Agents; Cote d'Ivoire; Dose-Response Relati

2017
Disseminated cryptococcosis in an HIV-positive boy.
    BMJ case reports, 2012, Oct-26, Volume: 2012

    Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Anti-HIV Agents; Antifungal Agents; Child; Cr

2012
Oral epithelial cell antifungal activity: approaches to evaluate a broad range of clinical conditions.
    Medical mycology, 2005, Volume: 43, Issue:6

    Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Candida; Candidiasis, Oral

2005
Successful treatment of Candida parapsilosis (fluconazole-resistant) osteomyelitis with caspofungin in a HIV patient.
    Scandinavian journal of infectious diseases, 2006, Volume: 38, Issue:8

    Topics: Candida; Candidiasis; Caspofungin; Drug Resistance, Microbial; Echinocandins; Fluconazole; HIV; HIV

2006
Pharmacokinetics of fluconazole after oral administration in children with human immunodeficiency virus infection.
    European journal of clinical pharmacology, 1995, Volume: 48, Issue:3-4

    Topics: Administration, Oral; Adolescent; Child; Female; Fluconazole; HIV; Humans; Male; Pharmacokinetics; T

1995
Withdrawal of fluconazole suppressive therapy for thrush in patients responding to combination antiviral therapy including protease inhibitors.
    AIDS (London, England), 1998, Dec-24, Volume: 12, Issue:18

    Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antifungal Agents; Candidiasis, Oral;

1998
AIDS and Africa.
    Biologist (London, England), 2000, Volume: 47, Issue:4

    Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Africa; AIDS Vaccines; Anti-HIV Agents; Antif

2000
Candidiasis at ICAAC.
    GMHC treatment issues : the Gay Men's Health Crisis newsletter of experimental AIDS therapies, 1995, Volume: 9, Issue:10

    Topics: Administration, Oral; AIDS-Related Opportunistic Infections; Antifungal Agents; Biological Availabil

1995